Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Solid Biosciences (SLDB) Income from Continuing Operations: 2016-2024

Historic Income from Continuing Operations for Solid Biosciences (SLDB) over the last 9 years, with Dec 2024 value amounting to -$120.6 million.

  • Solid Biosciences' Income from Continuing Operations fell 84.64% to -$38.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$120.6 million, marking a year-over-year decrease of 24.19%. This contributed to the annual value of -$120.6 million for FY2024, which is 24.19% down from last year.
  • As of FY2024, Solid Biosciences' Income from Continuing Operations stood at -$120.6 million, which was down 24.19% from -$97.1 million recorded in FY2023.
  • Solid Biosciences' 5-year Income from Continuing Operations high stood at -$72.2 million for FY2021, and its period low was -$120.6 million during FY2024.
  • Over the past 3 years, Solid Biosciences' median Income from Continuing Operations value was -$103.8 million (recorded in 2022), while the average stood at -$107.2 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first rose by 25.01% in 2020, then slumped by 43.84% in 2022.
  • Yearly analysis of 5 years shows Solid Biosciences' Income from Continuing Operations stood at -$88.3 million in 2020, then climbed by 18.24% to -$72.2 million in 2021, then tumbled by 43.84% to -$103.8 million in 2022, then grew by 6.48% to -$97.1 million in 2023, then fell by 24.19% to -$120.6 million in 2024.